
News|Articles|August 4, 2026
Pediatric eye care in H1 2026: Gene therapy momentum, one regulatory setback
Author(s)Kassi Filkins
The first half of 2026 turned on inherited pediatric eye disease, with 2 gene therapy programs advancing toward registration and a high-profile complete response letter in a childhood-onset optic neuropathy.
Advertisement
Advertisement
If the first half of 2026 had a throughline for children's eye health—it was inherited retinal and optic disease moving off the bench and toward the clinic. Two AAV-based programs cleared meaningful regulatory hurdles, while a closely watched optic neuropathy therapy stalled. Here is what pediatric and retinal specialists should have on their radar heading into the second half of the year.
Related to this article

BL1332 missed its 24-hour primary end point after PRK, though both doses showed numerically greater pain relief than vehicle.

Esen Akpek, MD, discusses how a systemic Sjögren disease therapy could change dry eye screening, referral and trial end points.

Six instructional courses at this year's congress in Florence follow artificial intelligence through retinal imaging, drug development, geographic atrophy care, and robotic surgery.

James Deom, OD, MPH, FAAO, FSLS, of Hazleton Eye Specialists, explains his baseline imaging approach, his nocturnal hypotension hypothesis and his same-day workup for patients on GLP-1 RAs who have sudden vision loss.

Eric Schlumpf discusses why Stuart Therapeutics is taking vezocolmitide beyond dry eye disease and into corneal wound healing.
Advertisement
Advertisement



